ConcertAI has recently acquired CancerLinQ, a subsidiary of the American Society of Clinical Oncology (ASCO), in a move aimed at revolutionising cancer care and accelerating clinical research. CancerLinQ is a major player in oncology real-world data and quality-of-care technology, with access to data from nearly seven million patients across over 100 cancer centres and practices.
The strategic acquisition involves a significant investment of over $250 million by ConcertAI to expand CancerLinQ's real-world data platform, integrate additional data sources, and deepen the understanding of cancer patients and their care.
The collaboration between ConcertAI and CancerLinQ is expected to yield several benefits. ConcertAI plans to leverage its Digital Access to Clinical Trial (DACT) platform to make patient participation in clinical trials more accessible and less burdensome. The integration of automated Electronic Medical Record (EMR) systems will streamline data integration, seamlessly incorporating the enhanced SmartLinQ™ platform into existing practice workflows. These advancements are designed to empower healthcare professionals with data-driven insights, facilitate informed treatment decisions, and expedite the development of new drugs and therapies through access to a diverse pool of real-world data.
The anticipated outcomes of this collaboration extend to various stakeholders in the healthcare ecosystem, including oncology practices, patients, and researchers. Oncology practices stand to benefit from an improved SmartLinQ™ platform and streamlined access to clinical trials, while patients can expect better access to treatment options and more personalised care plans.
Researchers are likely to experience accelerated development of new drugs and therapies, thanks to the collaboration's focus on leveraging real-world data for innovation in cancer care. Overall, the ConcertAI and CancerLinQ partnership holds great promise for advancing the landscape of cancer care and research.
Click here to read the original news story.